Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atomoxetine.

Dene Simpson1, Caroline M Perry

  • 1Adis International Inc., Yardley, Pennsylvania 19067, USA. demail@adis.com

Paediatric Drugs
|May 27, 2003
PubMed
Summary
This summary is machine-generated.

Atomoxetine, a nonstimulant medication for attention deficit hyperactivity disorder (ADHD), effectively reduced core symptoms in children and adolescents. Clinical trials demonstrated significant improvements in behavior and well-being with good tolerability and no abuse potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Drugs·2014
Same author

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Drugs·2014
Same author

Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Drugs·2014
Same author

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.

Drugs·2013
Same author

Simeprevir: first global approval.

Drugs·2013
Same author

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Paediatric drugs·2013
Same journal

Molluscum Contagiosum Treatments in Children: A Systematic Review with Network Meta-Analysis.

Paediatric drugs·2026
Same journal

Real-World Systemic Treatment Patterns and Outcomes of Children With Severe Alopecia Areata: A French Nationwide Study (ESTAPED ohort).

Paediatric drugs·2026
Same journal

Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians.

Paediatric drugs·2026
Same journal

Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance.

Paediatric drugs·2026
Same journal

Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort.

Paediatric drugs·2026
Same journal

Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis.

Paediatric drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Child and Adolescent Psychiatry

Background:

  • Atomoxetine is a selective norepinephrine reuptake inhibitor.
  • It represents a novel, nonstimulant therapeutic option for attention deficit hyperactivity disorder (ADHD).
  • Preclinical studies confirm its high selectivity for the norepinephrine transporter.

Purpose of the Study:

  • To evaluate the efficacy and safety of atomoxetine in treating ADHD in pediatric populations.
  • To assess the impact of atomoxetine on ADHD symptoms, psychosocial well-being, and problem behaviors.

Main Methods:

  • Four randomized, placebo-controlled clinical trials were conducted.
  • Participants included children and adolescents diagnosed with ADHD.
  • Treatment involved daily doses of atomoxetine (1-1.8 mg/kg) over 6-9 weeks.

Related Experiment Videos

Main Results:

  • Atomoxetine significantly reduced ADHD total scores compared to placebo (34-38% vs. 13-15.7%, p < 0.05).
  • Significant improvements were observed in ADHD subscale scores, psychosocial well-being, and parent/teacher-rated problem behaviors (p < 0.05, p < 0.001).
  • Adverse event discontinuation rates were low (<5%), with decreased appetite being the most common side effect.

Conclusions:

  • Atomoxetine is an effective and well-tolerated nonstimulant treatment for ADHD in children and adolescents.
  • The medication demonstrates a favorable safety profile with no identified abuse potential.
  • Atomoxetine offers a valuable alternative for managing ADHD symptoms and improving overall functioning.